Summary

Treatment with the A-type CpG oligodeoxynucleotide CYT003-QbG10 did not improve asthma control or lung function in patients with allergic asthma not adequately controlled with inhaled corticosteroids. This article presents data from the Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma [NCT01673672; Casale T et al. Am J Respir Care Med 2014].